🇺🇸 FDA
Pipeline program

Ferroquine SSR97193

DRI12805

Phase 2 small_molecule terminated

Quick answer

Ferroquine SSR97193 for Plasmodium Falciparum Infection is a Phase 2 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pasteur
Indication
Plasmodium Falciparum Infection
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials